Loading
Life sciences · Journal article
Cell Death Discovery · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Despite improved survival rates with dual trastuzumab and pertuzumab therapy, patients with HER2-positive breast cancer frequently experience disease progression due to intrinsic or acquired resistance. Elucidating the underlying mechanisms of resistance and identifying actionable therapeutic targets remain urgent clinical priorities. Endothelial cell adhesion molecule (ESAM) is a multifunctional protein implicated in tumor progression; however, its role in insensitivity to anti-HER2 therapy remains poorly understood. In this study, transcriptome sequencing revealed that ESAM is significantly upregulated in HER2-positive breast cancer patient-derived organoids (PDOs) with reduced responsiveness to trastuzumab and pertuzumab. Clinically, elevated ESAM expression correlated with poorer overall survival (OS), relapse-free survival (RFS), and disease-specific survival (DSS). Both in vitro and in vivo functional assays demonstrated that ESAM promotes cell proliferation and attenuates sensitivity to anti-HER2 therapy. Mechanistically, ESAM interacted with Calnexin, reduced its ubiquitination and proteasome-associated degradation, and prolonged its protein half-life, thereby activating mTOR signaling. Importantly, Calnexin depletion in ESAM-overexpressing cells attenuated mTOR activation and restored sensitivity to trastuzumab. Collectively, our findings identify the ESAM/Calnexin/mTOR axis as a candidate biomarker and therapeutic vulnerability in HER2-positive breast cancer.